JCR Pharmaceuticals has signed a licence agreement with Alexion, AstraZeneca Rare Disease, for its proprietary JUST-AAV capsids.

JCR Pharma signs agreement with Alexion for proprietary JUST-AAV capsids to develop genomic medicines: Hyogo, Japan Thursday, July 10, 2025, 10:00 Hrs [IST] JCR Pharmaceuticals Co ...

Merck & Co. Inc. has strengthened its cardiopulmonary pipeline with its $10 billion acquisition of London-based-Verona Pharma plc. The deal brings Merck Ohtuvayre (ensifentrine) for chronic ...

SGT-501 is a novel gene therapy for rare, life-threatening, genetic arrhythmogenic disease with no approved therapies - - SGT-501 has received Orphan Drug Designation and Rare Pediatric Disease Design ...

JCR announced that it has entered into a license agreement with Alexion, for JCR’s new, proprietary JUST-AAV capsids to ...

Receptor pharmacology articles from across Nature Portfolio Receptor pharmacology is the study of the interactions of receptors with drugs/pharmaceuticals and other xenobiotics. A basic tenet of ...

Nicotinic receptors — a family of ligand-gated ion channels that mediate the effects of the neurotransmitter acetylcholine — are among the most well understood allosteric membrane proteins ...

Under a new licensing deal announced July 8, JCR Pharmaceuticals Co. Ltd. granted Alexion Pharmaceuticals Inc. rights to its adeno-associated virus (AAV) capsids for use in up to five of Alexion’s ...